| T.R | Title | User | Personal
Name | Date | Lines |
|---|
| 486.1 | Short | KOALA::BOUCHARD | The enemy is wise | Tue Jun 01 1993 14:39 | 5 |
| Well, if such a rumor is causing a rapid run-up in the stock price then
it sounds like a good time to go short... and fire the broker passing
on such a rumor. But then again I'm not known as a particularly nice
person...
|
| 486.2 | Corection to Announcement! | WFOV11::CERVONE | | Tue Jun 01 1993 14:44 | 13 |
| OOPS, So I dont look like a fool I want to clarify the announcement.
I was looking over my notes and it said that Immune Response Corp.
at a conference in Berlin next week will have a very positive
announcement in regards to AIDS.
It could very well be a cure for AIDS, we just dont know quite yet but
the note again is "A Very Positive Announcement" in regards to AIDS.
Frank
|
| 486.3 | I'm not a pessimist but..... | MPGS::BEAULIEU | | Tue Jun 01 1993 18:08 | 13 |
| Based on what I have been reading/hearing from various sources, the
cure for AIDS is still a long way off. Although it would be wonderful
news, I think that it is extremely optimistic to think anyone will be
announcing that they have found a cure for AIDS next week. "A Very
Positive Announcement" could be any of a number of things and may even
be something that could eventually lead to a cure but based on the
complexity of the disease and what has been accomplished so far in
preventing/curing it I don't think that anyone has found a cure yet. Also,
keep in mind that many shares of stock are bought/sold based on emotion.
Rumors can (and often do) cause a stock's price to go up/down just as
easily as facts can. Be wary of buying stock in any company based on
rumors alone and be even more wary of a broker who would encourge you to
do so.
|
| 486.4 | Friday's Close | ODIXIE::GELINEAU | | Sat Jun 05 1993 11:28 | 5 |
|
I just had to check out the closing price for the week. 23 3/8s v.
26.50 from the original note!
|
| 486.5 | So similar to something else | KYOA::HANSON | Nostalgia ain't what it used to be. | Tue Jun 08 1993 11:47 | 16 |
|
Your best advice might, indeed, be to sell short.
This reminds me of a time 'bout 6 years ago when I got a "hot tip" on a
company called Medizone. It was rumored that they had a great
treatment for AIDS using ozone therapy. Lots of people bought in, ran
the stock up tremendously. Sensing that there was something amiss, I
cashed in at 1000% profit, and a month later, when Burroughs-Wellcome
came out with AZT, the Medizone stock all but dropped into oblivion.
When you're dealing with a plague like AIDS, so many people are quick
to think overly optimistically, fueling all sorts of rumors.
Then again, one never knows...
Bob
|
| 486.6 | Announcement Time 9:00 AM | WFOV12::CERVONE | | Tue Jun 08 1993 14:16 | 12 |
| The stock has been fluctuating up and down from the trading, it had
reached a high of $28.50 at one point.
Well tommorow is the day of the announcement in Berlin at the ninth
national AIDS conference. The time is 9:00 am but I'm not sure whether
it is Berlin time or our time.
It will be interesting to find out what the actual announcement is.....
wish me luck.
Frank
|
| 486.7 | 19 1/4 | ASD::DIGRAZIA | | Wed Jun 09 1993 13:02 | 6 |
|
At noon it was 19 1/4.
Maybe it will double this week...
Regards, Robert.
|
| 486.8 | Wow!! Why such a pounding? | WHOS01::SOUSA | | Wed Jun 09 1993 13:28 | 4 |
|
The stock is at 17 at about 12:30. From what I heard from the news
release, the new sounded very positive. Anyone have any idea why the
stock is getting killed?
|
| 486.9 | What did they say? | KYOA::HANSON | I'm tired of typing! | Wed Jun 09 1993 13:46 | 5 |
|
What was in the news release? Can you give us the basic gist?
/bh/
|
| 486.10 | | NOTIME::SACKS | Gerald Sacks ZKO2-3/N30 DTN:381-2085 | Wed Jun 09 1993 14:22 | 114 |
| <<< SICVAX::SICVAX$DUA1:[NOTES$LIBRARY]DVSN_MARKETS.NOTE;1 >>>
-< DowVision Markets >-
================================================================================
Note 4.10 Hourly List Fed Filings 10 of 42
SDSVAX::SWEENEY 107 lines 9-JUN-1993 09:18
-< IMNR/RPR Report P-II/III Results For HIV Vaccine >-
--------------------------------------------------------------------------------
Copyright � 1993 Dow Jones & Co. from Federal Filings
IMNR/RPR Report P-II/III Results For HIV Vaccine
FORM TYPE: FDA
ISSUER: IMMUNE RESPONSE CORP.
SYMBOL: IMNR
BERLIN, June 9 /PRNewswire/ -- The Immune Response Corporation and
Rhone-Poulenc Rorer Inc., through their joint venture Immunization
Products Limited (IPL), presented today results of a Phase II/III
clinical trial of an HIV-1 immunotherapeutic vaccine which demonstrated
an effect on viral burden and certain other surrogate markers.
The observation concerning viral burden was made using a state-of-
the-art HIV detection technique -- quantitative polymerase chain
reaction (PCR). The double-blind controlled clinical trial was
conducted in nine U.S. medical centers.
The presentation at the Ninth International Conference on AIDS
discussed results of a one-year study involving 103 asymptomatic
HIV-infected individuals. A statistically significant difference was
observed in the rate of increase of HIV in the blood (viral burden) in
treated as compared to control groups, as measured by the PCR assay.
This difference involved a lower rate of increase in the level of HIV in
treated patients as compared to those receiving the placebo control,
suggesting a stabilization in the treated group. The difference in
viral burden between treated and control groups was greater during the
second six months of study than in the first six months. Additional
analyses of this PCR data consistently favored the HIV immunotherapeutic
treated group. When using a qualitative co-culture method for virus
detection, a less sensitive measure of viral burden, no significant
differences were observed between the treated and control groups.
Although the study design anticipated the possibility of detecting an
overall reduction in viral burden by using both measures, PCR and the
co-culture method, a statistically significant difference in reduction
between the treated and control groups was not observed in this
analysis.
The trial also revealed the ability of the HIV immunotherapeutic to
stimulate an immune response against certain HIV proteins. A
statistically significant increase or stabilization in cell-mediated
immune responses to HIV proteins occurred in the treated group as
compared to a decline in the control group. Treated individuals also
exhibited greater increases in the levels of antibodies to p24, an HIV
core protein. These results are consistent with earlier studies
conducted with the HIV immunotherapeutic. A statistically significant
difference in weight gain, favoring the treated versus control group,
was also observed. Further analysis of the data from this trial is
ongoing.
Independent scientific researchers have reported that as HIV
infection progresses, the immune system weakens and the amount of virus
in the blood of HIV-infected individuals increases. The companies
believe the overall results of this trial indicate a treatment effect
upon these markers of progression. This effect may be of potential
benefit to HIV-infected patients. Although a statistically significant
difference was observed in this trial on surrogate markers, longer
follow-up is necessary to determine whether a clinical effect on
progression of disease will occur. Additional trials are planned over
longer periods of time and in individuals in various stages of infection
to determine the effect of the HIV immunotherapeutic on clinical
endpoints. IPL is continuing to work with the FDA to review the results
of this and prior studies to determine the appropriate next steps in
this program in accordance with the recently finalized regulations on
accelerated approvals for potential HIV therapies. Under these
regulations, once the FDA has completed review of the clinical data to
date, the agency, with the concurrence of the advisory committees, could
consider the appropriateness of these data to support a product license
application.
The underlying theory for the HIV immunotherapeutic, also referred
to as a therapeutic vaccine, was first proposed by Dr. Jonas Salk,
renowned for his pioneering work with the polio vaccine. The theory
behind Dr. Salk's approach is that it may be possible to slow disease
progression by enhancing protective immune responses in HIV-infected
individuals. The HIV immunotherapeutic, an envelope-depleted,
inactivated virus preparation, is being developed by Immunization
Products Limited.
The Immune Response Corporation is a biopharmaceutical company
engaged in the development of proprietary products for the treatment of
HIV infection, autoimmune disease, and, through TargeTech, Inc., its
wholly owned subsidiary, gene therapy and drug delivery.
Rhone-Poulenc Rorer Inc. is a global pharmaceutical company
dedicated to the discovery, development, manufacturing and marketing of
human pharmaceuticals. RPR had sales of $4.1 billion and research
expenditures of more than $500 million in 1992
(END) FEDERAL FILINGS-DOW JONES NEWS 06-09-93
09:26
---
opClass: N
opMode: I
messageType: N
timeStamp: 06/09/93 09:26
categoryCompany F.RHP, IMNR, RP, RPR
categoryIndustry I/BTC => Biotechnology, I/DRG => Drug Companies, I/MTC =>
Medical Technology
categoryGovernment G/FDA => US Food and Drug Administration
categorySubject N/HIY => Hourly List Fed Filings
categoryMarketSector M/NCY => Food and Health, M/TEC => Technology
categoryGeographic R/CA => California, R/NME => Northeast, R/PA => Pennsylvania
, R/US => United States
transmissionTime: 0927
originAddress: DJ
messageDate: 19930609
messageSequence: 0355
displayTime: 0926
rawSource: FF
accession: 199306090355
storyChecksum: 452463
storyLength: 4916
headlineLength: 48
|
| 486.11 | | NOTIME::SACKS | Gerald Sacks ZKO2-3/N30 DTN:381-2085 | Wed Jun 09 1993 14:23 | 83 |
| <<< SICVAX::SICVAX$DUA1:[NOTES$LIBRARY]DVSN_MARKETS.NOTE;1 >>>
-< DowVision Markets >-
================================================================================
Note 4.38 Hourly List Fed Filings 38 of 42
SDSVAX::SWEENEY 76 lines 9-JUN-1993 12:38
-< Salk Sees IMNR/RPR Vaccine Results As Pos. Trend >-
--------------------------------------------------------------------------------
Copyright � 1993 Dow Jones & Co. from Federal Filings
Salk Sees IMNR/RPR Vaccine Results As Pos. Trend
FORM TYPE: FDA
ISSUER: IMMUNE RESPONSE CORP.
SYMBOL: IMNR
Dr. Jonas Salk, in a briefing regarding the outcome of a Phase
II/III trial of Immune Response Co.'s and Rhone-Poulenc Rorer's HIV
ImmunoTherapeutic vaccine, called the results the "first whiff of
spring," indicating some hope as to the paths to pursue for an
appropriate treatment.
Salk said nothing clinically meaningful can yet be done with
the HIV ImmunoTherapeutic, but that results show that the vaccine is
worth pursuing.
As reported earlier, Immune Response and Rhone-Poulenc Rorer
presented data from a Phase II/III trial at the ninth International
Conference On Aids held in Berlin today. The results showed that
treated patients exhibited a stabilization in viral burden, or the
amount of virus present in the infected patient, and a greater immune
response to HIV than in the placebo patients.
The patients were treated at zero, three, and six months.
Viral burden was measured by the amount of virus present in the blood.
Although most HIV is located in the lymph nodes, a decrease of HIV
present in blood would probably indicate a decrease of virus in the
lymph nodes, according to the researchers. Immune system response was
assessed ex vivo at monthly intervals by observing antibody activity
against the virus.
Salk added that although the viral burden overall in the
treated patients increased only 10% as compared to a 48% increase in
the non-treated patients, when the patients were broken into three
groups one group saw a decrease in viral burden, the second saw a
stabilization, and the third saw an increase. Salk said that a greater
number of patients saw some decrease in viral burden.
A decrease in viral burden was more likely in patients not as
far into the disease progression, indicating that earlier treatment
would yield better results. Salk suggested that this would indicate the
need to titrate treatment according to time of infection.
Drs. Alexandra Levine, of the University of Southern
California, and Dennis Carlo of Immune Response joined Salk's assessment
that the data were not clinically meaningful but did identify a trend in
that direction. All three researchers said that greater follow up in
treated patients is needed to adequately determine possible
immunological responses and that these results would provide and
architecture for future studies.
The HIV ImmunoTherapeutic is composed of a killed gp 120 virus
stripped of its protective envelope. The vaccine is not meant to
prevent contraction of HIV but to allow heathy infected patients to live
with their disease by stimulating antibody reaction to arrest disease
progression
(END) FEDERAL FILINGS-DOW JONES NEWS 06-09-93
12:48
---
opClass: N
opMode: I
messageType: N
timeStamp: 06/09/93 12:48
categoryCompany F.RHP, IMNR, RP, RPR
categoryIndustry I/BTC => Biotechnology, I/DRG => Drug Companies, I/MTC =>
Medical Technology
categoryGovernment G/FDA => US Food and Drug Administration
categorySubject N/HIY => Hourly List Fed Filings
categoryMarketSector M/NCY => Food and Health, M/TEC => Technology
categoryGeographic R/CA => California, R/NME => Northeast, R/PA => Pennsylvania
, R/US => United States
transmissionTime: 1249
originAddress: DJ
messageDate: 19930609
messageSequence: 0442
displayTime: 1248
rawSource: FF
accession: 199306090442
storyChecksum: 249631
storyLength: 2782
headlineLength: 48
|
| 486.12 | Title: Immune Resp (IMNR) V-Alert: -5 7/8 At 15 3/4 On 4,047,200 -NEWS
Keywords: IMNR Title: Immune Resp (IMNR) V-Alert: -5 7/8 At 15 3/4 On 4,047,200 40 lines | CADSYS::BOLIO::BENOIT | | Wed Jun 09 1993 16:53 | 40 |
| Copyright � 1993 Dow Jones & Co. from Professional Investor Report
Immune Resp (IMNR) V-Alert: -5 7/8 At 15 3/4 On 4,047,200 -NEWS
IMMUNE RESPONSE CORP.
Last trade NMS: -5 7/8 at 15 3/4 on zero tick
Trade vol: 1,000 = 0.0% ttl vol= 0.0% shrs out
Ttl blk vol: 1,386,600 = 34.3% ttl vol= 9.1% shrs out
Avg blk vol: 176,383 = 33.9% avg daily vol
Ttl vol: 4,047,200 = 778.4% avg daily vol
Avg daily vol: 519,962 / Prev day -3 on 1,852,600
Rhone-Poulenc, Co. Say Vaccine Promising
Vaccine Helps Response Vs Some HIV Proteins
Co: HIV Increaese In Blood Slowed By Vaccine
(END) DOW JONES NEWS 06-09-93
3:37 PM EDT
---
opClass: N
opMode: I
messageType: N
timeStamp: -0- 3 37 PM EDT 06-09-93
categoryCompany IMNR
categoryIndustry I/BTC => Biotechnology, I/MTC => Medical Technology
categorySubject N/ALT => Alerts
categoryMarketSector M/TEC => Technology
categoryGeographic R/CA => California
categoryStatistical S/VOA => Volume Alert
transmissionTime: 1552
originAddress: DJ
messageDate: 19930609
messageSequence: 0600
displayTime: 1537
rawSource: PI
originalSource: PI
accession: 000000000000
storyChecksum: 37377
storyLength: 540
headlineLength: 63
|
| 486.13 | Title: Immune Resp (IMNR) V-Alert: -2 1/4 At 13 3/4 On 955,300 | CADSYS::BOLIO::BENOIT | | Thu Jun 10 1993 11:20 | 36 |
| Copyright � 1993 Dow Jones & Co. from Professional Investor Report
Immune Resp (IMNR) V-Alert: -2 1/4 At 13 3/4 On 955,300
IMMUNE RESPONSE CORP.
Last trade NMS: -2 1/4 at 13 3/4 on zero tick
Trade vol: 1,000 = 0.1% ttl vol= 0.0% shrs out
Ttl blk vol: 216,500 = 22.7% ttl vol= 1.4% shrs out
Avg blk vol: 201,252 = 33.9% avg daily vol
Ttl vol: 955,300 = 161.1% avg daily vol
Avg daily vol: 592,865 / Prev day -5 5/8 on 4,822,100
(END) DOW JONES NEWS 06-10-93
10:02 AM EDT
---
opClass: N
opMode: I
messageType: N
timeStamp: -0- 10 02 AM EDT 06-10-93
categoryCompany IMNR
categoryIndustry I/BTC => Biotechnology, I/MTC => Medical Technology
categorySubject N/ALT => Alerts
categoryMarketSector M/TEC => Technology
categoryGeographic R/CA => California
categoryStatistical S/VOA => Volume Alert
transmissionTime: 1017
originAddress: DJ
messageDate: 19930610
messageSequence: 0179
displayTime: 1002
rawSource: PI
originalSource: PI
accession: 000000000000
storyChecksum: 25548
storyLength: 397
headlineLength: 55
|
| 486.14 | Just a guess... | KYOA::HANSON | I'm tired of typing! | Thu Jun 10 1993 12:09 | 15 |
|
First whiff of spring might be right, but we get back to the question
of why the stock isn't doing as well as you had expected.
Could it be that the initial "rumors" in pre-announcement ran the stock
up significantly, with everyone hoping for more positive news? Seems
to me that while the news is rather promising (let's pray for a cure!),
it's not as earth-shattering as one might have hoped for...including
those on the Street.
Watch this carefully. It again reminds me of Medizone, as mentioned a
couple of replies back.
Bob
|
| 486.15 | Not immune to mistakes, I respond | VMSDEV::HALLYB | Fish have no concept of fire | Thu Jun 10 1993 13:03 | 6 |
| .0> I've heard from my broker and so far my broker has a good track record,
We all make bad calls, but somehow the broker still makes money even
when he flubs up...
John
|
| 486.16 | Who Knows This is Just a Big Poker Game!! | WFOV11::CERVONE | | Thu Jun 10 1993 14:21 | 25 |
| Well you've all been reading it so there is no need for me to add any
more to what has already been said.
Its not the first and I'm sure it wont be the last bad call my broker
will make, but I do know that he bought options that are now worthless.
It still has a ray of hope, again the news is positive but I beleive
what the investor was looking for is the miracle cure. Through some
research my broker has found out that they are very close to the cure
like one step away so at this point we have no choice but to hold.
Unfortunately no one said it would be easy investing in the market and
this is one of the down side of it all. Youve got to be able to take
the bad news as well as the good news. But I'm a baby so I'll through a
tantrum beat the sh_t out of my broker and get on with it.
There was another positive article in the WSJ today I would
appreciate the print out if it is readily available to anyone, I do not
subscribe to the WSJ. Thanks in advance.
Frank
|
| 486.17 | More information on Immune | KYOA::HANSON | I'm tired of typing! | Thu Jun 10 1993 16:49 | 12 |
|
Just saw this in todays issue of USA Today (6/10/93) :
"Immune Response slumped 5-5/8 to $16. The company announced results
for its one-year Phase II/III trial of a therapeutic vaccine for AIDS.
The data were "interesting but inconclusive," Cown analyst David Stone
told Bloomberg Business News. He added that there isn't enough hard
data yet for Immune to win Food and Drug Administration clearance for
the vaccine."
/bob/
|
| 486.18 | | TLE::COLLIS::JACKSON | Roll away with a half sashay | Fri Jun 11 1993 14:39 | 7 |
| >Through some research my broker has found out that they are very close to
>the cure like one step away so at this point we have no choice but to hold.
That's not what I read.
That's not what I'd believe.
|
| 486.19 | No magic bullet | KOALA::BOUCHARD | The enemy is wise | Mon Jun 14 1993 12:15 | 7 |
| re: .18
I agree completely. The announcement represents a medical advance, and
any advance is a tremendous thing, but it is only a relatively small
step. The scientific report certainly doesn't claim that a
breakthrough is imminent...
|
| 486.20 | More To Come.............. | WFOV12::CERVONE | | Mon Jun 14 1993 13:42 | 19 |
|
I could be wrong but I've got no choice but to wait, I've talked with my
broker and he has been told that IMNR has downplayed the anouncement to
the public because of the FDA. They will be licenced by Aug. and they
will have another announcement somtime in mid July.
No magic bullet yet and I certainly dont know whether there will be, but
if I thought it was a total loss I would have gotton out by now. My
broker and I have worked well together and I believe in his
recommandation. Although it was going to be a stock play, knowing that
it was volitle and risky it has now become a hold. I do not want to be
marrried to this stock so I will keep my eyes open and watch very carefully.
I thank you all for all the advice and certainly appreciate it.
Frank
|
| 486.21 | Hmmm?????/edit | WHOS01::SOUSA | | Mon Jun 14 1993 15:09 | 10 |
|
re: .-1
First off, I want to wish you the best of luck, I have experienced
these kind of drops before and know how stressful they can be. But it
seems kind of odd that your broker would have that kind of positive
"inside" information, while the rest of the street dumps the stock. Do
you know what his sources are???
Just curious, and again, good luck.
|
| 486.22 | <But the rumor - sell the news!> | ODIXIE::GELINEAU | | Fri Jun 18 1993 19:46 | 1 |
|
|
| 486.23 | Here's Hoping the Broker is Right Again. | WFOV11::CERVONE | | Mon Jun 21 1993 13:30 | 32 |
| RE: .21
He has a partner that he works with and his partner is getting info
from the inside. I dont know exacticaly who! I plan on asking him.
I was contacted on the same week the stock had some rumors of the news
and wouldn't you know it my broker left a bucnch of messages on my
phone, but I was on vacation. At the time he called the stock was
trading in the $15 dollar range by the time I got back after Memorial
day the stock was trading at $23. You know the rest of the story.
It was going to be a lot bigger and better than it was played out to
be. The potential for the stock at that time was to be in the high
$50's or better so we chased the stock and bought at the range we did.
The inside info is still that good, we are being told and from the cycles
the company goes thru that the stock still has a potential of being in the
$30 to $60 range in the very near future. It is a wild shot but I've come
to see the whole market that way through my experiences good and bad. I
don't go to Atlantic City but I gamble in the stock market because I
believe in the long run you can beat it.
RE: .22 But the rumor - Sell on the news
That was our intention but the news was downplayed and it was taken
with skepticism. The company insider says they will be licenced by Aug
and there will be another anouncement in July. The stock itself is a
cyclicle stock it runs up in July time frame on no news at all.
Frank
|
| 486.24 | Any update | WHO302::SOUSA | | Wed Jul 07 1993 13:53 | 5 |
|
Any idea what the announcement will be in July?? Also, does he/she
think they will be licensed to actually sell a product come August??
The stock seems to have settled in the 12-13 dollar region!
|
| 486.25 | Just waiting for Announcement | WFOV11::CERVONE | | Thu Jul 08 1993 13:53 | 10 |
|
Dont know exacticaly what the announcement will be, but it is going to
be about the vaccine they have been working on. He thinks they will
be FDA approved for the vaccine and should be able to sell it.
Frank
|
| 486.26 | FDA Approval Soon | WFOV12::CERVONE | | Thu Jul 15 1993 13:23 | 22 |
|
An update for followers and investors of IMNR.
Still holding............................
I got an update today, it looks real good the vaccine is working and it
seems to be stopping the HIV while building the Immune system up again.
This is much better then the AZT vaccine which just slows it down.
Just waiting for FDA approval and IMNR is not pushing. But they (IMNR)
feels so strong of the vaccine that if the FDA drags their feet they will
have no choice but to push.
I believe that if IMNR gets FDA approval it will make AZT obsolete. It
would also put some others out there out of bsiness. The only problem
now is pushing for aproval.
Frank
|
| 486.27 | AZT | DSSDEV::HAUBNER | | Mon Jul 19 1993 11:36 | 7 |
|
FYI - AZT is not a vaccine. If we are going to get rich on the cure for AIDS
perhaps a little education on the HIV virus and current treatment strategies
would be of benifit. I'm not suggesting that this conference is the proper
forum for such education.
Wayne
|
| 486.28 | Soon I hope - too many people are dieng | WFOV11::CERVONE | | Mon Jul 19 1993 13:19 | 14 |
|
Sorry!!!!!!!!!!
I dont know anything about AZT and I certainly was not aware that it
wasn't a vaccine. I guess I'm just showing optimisim that there may be
some hope out there for those that have the HIV virus and that one of
these days there will be a cure.
I certainly was not trying to knock AZT it has helped I'm sure but the
next logical step is to find the cure.
Frank
|
| 486.29 | Quarterly earnings tomorrow | WHO302::SOUSA | | Wed Jul 21 1993 12:24 | 6 |
|
I just spoke to someone in Investor Relations at Immune Response. They
told me that they are reporting their quarterly earnings tomorrow
before the market opens. She said that it would definetly be a loss,
and that as far as she knew, they had no other announcements regarding
the drug/vaccine/whatever it is!!!
|
| 486.30 | | ZENDIA::FERGUSON | Your recipe is so tasty | Wed Jul 21 1993 14:34 | 1 |
| as of now, stock is 10 3/4 unchanged, bid is 10 1/4, volume 55,000
|
| 486.31 | Should not effect the stock | WFOV12::CERVONE | | Wed Jul 21 1993 14:51 | 21 |
|
IMNR has never posted earnings in other words it has never made money,
it is a reaserch and development company and that is what i'm banking on
for the profit on my investment.
Its Debt to Equity is very small. I dont believe the stock will be
effected much if any by the announcement. They are lookiing to be
licenced to sell the drug/vaccine by Aug time frame and thats when we
should see a big movement in the stock.
As far as the announcement in July I believe I read the information
wrong and basicaly the rumor is that the annoucement should be or will
be when they get FDA approval and are abel to sell the vaccine.
If you dont mind I would like the phone number for Investor Relations at
Immune Response, I would like to call and ask for some info myself.
Thanks
Frank
|
| 486.32 | (619)-431-7080 | WHO302::SOUSA | | Thu Jul 22 1993 09:39 | 3 |
| That's the main number. Ask for Investor Relations!!!
Good Luck!
|
| 486.33 | For Interested Parties | WFOV12::CERVONE | | Thu Jul 22 1993 13:10 | 5 |
| Thank you for the number
For all interested, I will post news here as I get it.
Frank
|
| 486.34 | Hoping for FDA Approval Soon! | WFOV12::CERVONE | | Wed Aug 04 1993 14:00 | 21 |
|
My broker has been working very hard to stay on top of what is going on
with IMNR. I beleive in the info he has been getting because I have
confirmed it with Investor Relations at IMNR.
The latest is this, IMNR is waiting for FDA approval, Inv. Relations
said they can not say a lot about it and they can't put a specific
date on the approval, it could be sometime before the end of the year
or it could be as close as tommorow. Interesting as close as tommorow!
Also the insider that is providing the information has given his broker
my brokers partner 2,000 shares of stock cirtificates on IMNR to be
sold at get this $70.00 per share. If they get FDA approved this price
is not out of the relm, and is what we are looking at for a potential. I
bought more shares at this price level and I will by more as soon as
the price starts to inch its way up to average my price down and for
optimum potential in profit.
Frank
|
| 486.35 | | ZENDIA::FERGUSON | Your recipe is so tasty | Wed Aug 04 1993 16:01 | 1 |
| IMNR, $10.00, -1/4, vol 207k, as of 14:52 today.
|
| 486.36 | ACT UP - Rally RPR/IPL/IMNR | WFOV11::CERVONE | | Wed Aug 11 1993 14:14 | 112 |
| UPDATE ON - IMNR
Last week sometine on Aug 3rd or 4th to be exact ACT UP/Philadelphia
sponsered a rally targeted at RPR - Rhone-Ppoulenc-Rorer The make of
the Salk Therapeutic vaccine.
ACT UP is demanding access to the vaccine now!
To make a long story short I will only list the important facts of the
rally and explicit the point of view of both sides.
On Sept 16, 1992 RPR said: This drug is a number one priority we expect
to make vaccine late in winter and want to hava a clinical trials by
summer.
ACT UP responded - there are 900 patients in Philadelphia who are
impatiently waiting for trials. We are stunned you are not further
along and even though the tough problems in scaling up productions have
not been solved, there still is no plan as of July 21, 1993.
RPR said on July 9th "We are now begining to work on plans for large
clinical trials".
ACT UP responded - Simple question. Why aren't these completed on the
shelf and approved by the FDA pending availability of active drug???
Even if you want to modify the plans to include new data or new markers
the task of getting the plan through the FDA becomes simplified.
RPR said on July 21st "The drug is very hard to make and the production
issues are complex".
ACT UP responded - You should be proud to show us your plans, show us the
critical path and tell us when you pan to have the drug.
RPR - "We want to work with the Amfar network on trials, but we want
other sites as well".
ACT UP - COME ON make a commitment. Any trials network will probably be
able to do only one or two large vaccine trials. If you are serious you
would be talking contract terms with trial sites.
RPR - "We cant give you a date on when vaccine will be available. We
don't know".
ACT UP - Should the 900 patients who are signed up for vaccine trials
move on to other drugs? other trials? Would you wait-RPR/IPL???
RPR Annual Report - "If the data from this trial are positive these
results may support a 1993 submission under the new accelerated
approval guidelines of a PLA to the FDA requesting permission to market
the HIV Immunotherapeutic in the US".
ACT UP - Will trial patients get drug for free? What plans do you have
to supply those who have Impatienltly awaited these trials.
1. We want a formal commitment to the Public Forum and the Focus Groups
with AIDS patients to which you jave already agreed. No promises -
dates!
2. We want Activists attendence at your Aug 12, 1993 Science Meeting
3. We want the management of the project and some of your corp
management to visit the Betak AIDS Nursing Home, and we want you to
meet some real living AIDS patients.
4. We want you to show us the same sense of urgensy we have shown you.
We want you to commit in writing to those 103 trials both subjects and
controls at least 3 additional doses of vaccine Immediatly upon
availability. We want to see you resulting in anticipation of drug
reciept of FDA approval.
STANDBY STATEMENT BY - RPR At Demonstration At Corp. Headq.
RPR welcomes dialogue with members of the HIV Community. We are
sensitive to patient needs to bring HIV therapies to the market faster.
A demonstration however, can only slow down the levelopment process to
our mutual goals.
At RPR the HIV Immunotherapeutic is one of our two top research
projects. Through Immunization Products Limited, our joint venture
with the Immune Response Corp. our clinical development efforts has
demonstrated the SAFETY AND IMMUNOGENICITY of this product. In
tradition our recently completed surrogate market trial (Phase II/III)
demonstrated a treatment effect on viral burden. Clinical endpoint
trials (Phase III) are in the planning stage. We are working
diligently to bring this new treatment to patients as quickly as
possible.
Overall it looks good my broker has been supplying me with all the
information and I have hard copies for anyone interested on reading the
whole blowdown I am willing to forward to you.
I also believe that maybe the short sellers and the big players in this
stock have seen the last of the shake down from the small invester. the
stock is at bargain price. Today there is some high volume and it is
at 10 up 5/8 volume at 1:00 pm about 500,000.
For all his hard work I believe my broker needs some recocnition If you
are interested in finding out more aboutd it or looking to invest in
IMNR give him a call.
Name: Barney Kowalski with Cohig & Associates
Phone: 1-800-333-2622
Thanks and good luck
Frank
|
| 486.37 | IMNR meeting with FDA | WFOV11::CERVONE | | Mon Sep 13 1993 14:06 | 6 |
|
On Sept. 10, 1993 I heard of a rumor that IMNR and RPR will be meeting
with the FDA for the aids vaccine.
|
| 486.38 | ELABORATE PLEASE | WHOS01::SOUSA | | Tue Sep 14 1993 09:28 | 4 |
|
FRANK,
COULD YOU ELABORATE ON YOUR LAST COMMENT PLEASE??
|
| 486.39 | IMNR in Barrons Stock to Watch | WFOV12::CERVONE | | Mon Feb 01 1993 06:19 | 8 |
| Last week Barrons had an article on IMNR, somthing to the fact that it
is a stock to watch (HOT) or somthing.
Does anyone have or read the article I would appreciate a copy or even
posting it in here.
Thanks
Frank
|
| 486.40 | 9/20/93 Barron's | LEDS::DJBROWN | | Tue Sep 28 1993 13:13 | 11 |
| There's an article in the 9/20/93 Barron's by Lissa Morgenthaler, who
writes for the California Technology Stock Letter. The article reviews
about 15 companies with genetic-therapy research. No recommendations,
just descriptions. There are two sentences on Immune Response,
reprinted below without permission.
"Another company, Immune Response, of Carlsbad, Calif., is the proud
possessor of TargeTech, a therapy that uses a delivery system that
links naked DNA to a protein. One problem that's cropped up is the
penchant of lysosomes (essentially, a cell's digestive tract) for
scarfing down TargeTech's proteins before they can do their work."
|
| 486.41 | IMNR Moving up Again | WFOV12::CERVONE | | Wed Oct 13 1993 12:15 | 17 |
| There is no news as of yet but IMNR has been inching its way upward
again. I believe that they have met with the FDA as my previous note
stated but have not released any info yet.
Today the stock is up to 13 3/4 bid to 14 asked. Up a total of 5
points from last week.
I believe this is the begining of the climb back to its 30 dollar price
range of 4 months ago. And from what Investor Relations said they
should be approved to market the drug late fall or early spring.
If there are any interests in the stock I aslo beleive now is the time
before any announcements are made, because once the announcements are
made there is no stopping the stock.
Frank
|
| 486.42 | technical charts | DANGER::LEAHY | stresstab addict | Thu Oct 14 1993 10:48 | 16 |
|
I downloaded 2 years worth of historical data on IMNR last
night. I've printed some postscript technical charts that can
be copied from danger::flaguser1:[leahy.m80]
imnr_hilo.ps, imnr_rsi.ps and imnr_sto.ps
the first one is a hi-lo-volume chart, the second contains
the RSI indicator (relative strength indicator) and the third
contains the stochastics indicator.
jim
|
| 486.43 | | USCTR1::BJORGENSEN | | Tue Oct 26 1993 09:17 | 6 |
| Just heard on the radio this am (BCN) that a French research firm (they didn't
make mention of the name) had made "significant" progress in aids research,
and "would have a vaccine in the near future".
Obviously, very ambiguous. There were no more details given. If it is really
significant, I'm sure that we will see something in the papers.
|
| 486.44 | IMNR Granted Patent for Vaccine!!! | WFOV11::CERVONE | | Thu Oct 28 1993 13:16 | 19 |
| The article I read stated that they are very far avay from even
considering a vaccine. There is a lot of testing before they could
even get close to the point that IMNR is at . This French research
firm has only been testing mice and rats thus far.
On the other hand I heard of some good news on the DOW for IMNR
(If anyone can pull it in I would aooreciate it).
IMNR has been given a patent on the vaccine they have been working with
and is now very aggressively working with the FDA twards the next
logical step to proceed to.
Frank
|
| 486.45 | IMNR NEWS RELEASE | WFOV11::CERVONE | | Fri Oct 29 1993 12:51 | 59 |
|
The Immune Response
Corporation
N E W S R E L E A S E
October 27, 1993 Contact:
Bronwyn Lemelle, or
Cindy Rollins, Investor Relations
(619) 431-7080
For Immediate Release
The Immune Response Corporation
Receives U.S. Patent on HIV Technology
CARLSBAD CA -- October 27, 1993 -- The Immune Response
Corporation (NASDAQ/NMS Symbol: IMNR) today announced the issuance of a
United States patent relating to its HIV immunotherapeutic. The United
States patent # 5,256,767 entitled "Retroviral Antigens", names Drs.
Jonas Salk and Dennis J. Carlo as inventors and covers an HIV particle
free of outer envelope proteins.
The Immune Response Corporation, Together with its Joint venture
partner, Rhome Poulenc-Rorer Inc., is using this patent technology to
develop its HIV immunotherapeutic to treat HIV infected individuals.
The product is designed to boost the immune system and thereby allow
the body's normal defense mechanism to control the virus.
A multi-center Phase II/III clinical trial with the HIV
immunotherapeutic has been completed. The joint venture is continuing
to work with the FDA to review the results of this and prior studies to
determine the appropriate next steps in this program in accordance with
the FDA regulations on an accelerated approvals for potential HIV
therapies.
"The allowance of broad composition of matter claims for out HIV
immunotherapeutic enable us to establish a strong position," said Dr.
Carlo, Chief Scientific offices of the Immune Response Corporation.
FDA approval is required prior to marketing.
The Immune Response Corporation is a biopharmaceutical company
engaged in the development of proprietary products for the treatment of
HIV infection and autoimmune diseases and, through Targetech, Inc.,
gene therapy.
Reprinted Withought Permission
Frank
|
| 486.46 | Dr Salk to meet with H. Clinton?? | WFOV12::CERVONE | | Thu Dec 30 1993 09:27 | 11 |
| Just a short note on developments on the FDA approval of the
inmunotheraputic (sp) vaccine. Rumors have it that Dr. Jonas Salk of
IMNR will be meeting with Hillary Clinton to discuss the vaccine
developed by IMNR. His concerns are the amount of time it is taking for
FDA approval. It appears that Dr. Salk firmly believes that this
vaccine can help those afflicted with AIDS.
Has any one else heard of this development?
Please respond.
Frank
|
| 486.47 | IMNR & RPR Joint Venture...... | WFOV12::CERVONE | | Wed Feb 16 1994 14:07 | 75 |
| For those of you who are invested in IMNR and or just following it.
Dow Jones News - Reprinted withought permission
From: Jamie Hirschfeld
Immune Responce
2-:Will still develop HIV Immunotherapeutic
CARLSBAD, Calif. -DJ- Immune Responce Corp. (IMNR) and Rhome-Poulenc
Rorer Inc. (RPR) are proceeding to arbitration to resolve certain
issues regarding the management of their joint venture, Immunization
Products Ltd.
The companies seek to resolve issues regarding their joint and
individual responsibilities concerning the research and development of
their HIV immunotherapeutic.
Dr. Dennis Carlo, executive vice president and operating chief of
Immune Responce, said in a press release that "the differences concern
management issues rather than interest or enthusiasm for the joint
venture. Both we and Rhome-Poulenc Rorer intend to continue to
actively pursue the development of the HIV immunotherapeutic during the
course of the arbitration proceedings. The goal of the joint venture
remains to bring this treatment to HIV-infected patients as quickly as
possible."
Immune Response said the HIV immunotherapeutic is based on a
scientific approach proposed by Dr. Jonas Salk, the developer of the
first successful polio vaccine. It's designed to prevent or delay
progression of HIV infections to AIDS by stimulationg a patient's
immune system to attach the virus.
(MORE) DOW JONES NEWS 02-14-94
11:19 AM
-- 11 19 AM EST 02-14-94
From: Jamie Hirschfeld
Immune Responce
-3-: Meeting with FDA Requested >IMNR RPR
In a separate release, Michael de Rosen, President and operating
chief of Rhome-Poulenc, said that since the joint venture was formed, a
series of achievements have been registered. We completed a Phase
II/III study (103), analyzed all study data, completed a clinical
development plan, BUILT A DEDICATED MANUFACTURING SITE and opened
dialouge with the scientific and patient communities.
"Unfortunately, during this process. it has become apparent that
differences exist between the two companies concerning the best way to
investigate and develop the HIV immunotherapeutic. To obviate any
impact on th project and the AIDS community, we have filed for
arbitration. Of course, the goal is to continue to accelerate the
evaluation of this compound's safety and efficacy via a scientifically
driven development effort that meets both regulatory standards and the
overal needs of the AIDS community," he said.
In late December of 1993, the joint venture submited the medical
summary from the Phase II/III clinical trial to the Food and Drug
Administration and a meeting with the FDA has been requested to discuss
the results of this trial, Rhome-Poulenc said.
(END) DOE JONES NEWS 02-14-94
11:25 AM
-0- 11 25 AM EST 02-14-94
|